tiprankstipranks

Quest Diagnostics price target raised to $155 from $152 at JPMorgan

JPMorgan raised the firm’s price target on Quest Diagnostics to $155 from $152 and keeps a Neutral rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue